Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
The two longer-term headwinds facing GLP-1 drugs — Medicare negotiations going into effect in 2027 and the patent cliff for semaglutide in 2032 — are why the company has already started ...
Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...
And the inclusion of the semaglutide drugs — Wegovy for weight ... the biggest reason Novo isn't overly concerned is because Medicare is not its largest market in the US. Until the start of ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
13don MSN
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...
2don MSN
Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...
USA TODAY on MSN20d
Here's why researchers think most people stop taking weight loss drugs within a yearNearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.
Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results